Safety and Side Effects of Immediate Instillation of Apaziquone Following Transurethral Resection in Patients With Nonmuscle Invasive Bladder Cancer

Journal of Urology

Volumn 180, Issue 1, 2008, Pages 116-120

  Hendricksen, K ^a   Gleason, D ^b   Young, J M ^c   Saltzstein, D ^e   Gershman, A ^d   Lerner, S ^f   Witjes, J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Advanced Clinical Therapy ^*  (United States)

^c South Orange County Medical Research Center   (United States)

^d Institute for Advanced Urology   (United States)

^e Urology San Antonio Research   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

adjuvant; administration; chemotherapy; EO 9; intravesical; urinary bladder neoplasms

Indexed keywords

APAZIQUONE;

ABDOMINAL PAIN; ARTICLE; ASTHENIA; BLADDER CANCER; BLADDER MUCOSA; BLADDER SPASM; BLEEDING; BLOOD SAMPLING; CANCER PATIENT; CANCER SURGERY; CLINICAL TRIAL; CYSTITIS; CYSTOSCOPY; DIABETES MELLITUS; DIZZINESS; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; DYSURIA; FEVER; FLANK PAIN; HEMATURIA; HUMAN; LYMPHADENOPATHY; NAUSEA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINARY URGENCY; URINE RETENTION; WOUND HEALING IMPAIRMENT;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZIRIDINES; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDOLEQUINONES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSPECTIVE STUDIES; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 44649134502     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.03.031     Document Type: Article

References (21)

1. Kirkali Z., Chan T., Manoharan M., Algaba F., Busch C., Cheng L., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 (2005) 4
2. Oosterlinck W., Lobel B., Jakse G., Malmstrom P.U., Stockle M., and Sternberg C. Guidelines on bladder cancer. Eur Urol 41 (2002) 105
3. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186
4. Hall M.C., Chang S.S., Dalbagni G., Pruthi R.S., Seigne J.D., Skinner E.C., et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178 (2007) 2314
5. Oosterlinck W., van der Meijden A.P., Sylvester R., Boehle A., Rintala E., Solsona Narvón E., et al. Guidelines on TaT1 (non-muscle invasive) bladder cancer. Guidelines, European Association of Urology (2006), Drukkerij Gelderland bv, Arnhem, The Netherlands 3-17
6. van der Heijden A.G., Moonen P.M., Cornel E.B., Vergunst H., de Reijke T.M., van Boven E., et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176 (2006) 1349
7. Mostofi F.K., Torloni H., and Sobin L.H. Histological typing of urinary bladder tumours. International classification of tumors 10 (1973), World Health Organization, Geneva
8. Sobin L.H., and Fleming I.D. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80 (1997) 1803
9. Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Hillebrand MJ et al: Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry. J Mass Spectrom 206; 41: 1268.
10. Brausi M., Collette L., Kurth K., van der Meijden A.P., Oosterlinck W., Witjes J.A., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523
11. Kaasinen E., Rintala E., Hellstrom P., Viitanen J., Juusela H., Rajala P., et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42 (2002) 167
12. Pan J.S., Slocum H.K., Rustum Y.M., Greco W.R., Gaeta J.F., and Huben R.P. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. J Urol 142 (1989) 1589
13. Tolley D.A., Parmar M.K., Grigor K.M., Lallemand G., Benyon L.L., Fellows J., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155 (1996) 1233
14. Bouffioux C., Kurth K.H., Bono A., Oosterlinck W., Kruger C.B., de Pauw M., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153 (1995) 934
15. Workman P., Binger M., and Kooistra K.L. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. Int J Radiat Oncol Biol Phys 22 (1992) 713
16. McLeod H.L., Graham M.A., Aamdal S., Setanoians A., Groot Y., and Lund B. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group. Eur J Cancer 32A (1996) 1518
17. Collado A., Chechile G.E., Salvador J., and Vicente J. Early complications of endoscopic treatment for superficial bladder tumors. J Urol 164 (2000) 1529
18. Oddens J.R., van der Meijden A.P., and Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?. Eur Urol 46 (2004) 336
19. Oosterlinck W., Kurth K.H., Schroder F., Bultinck J., Hammond B., and Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149 (1993) 749
20. Witjes J.A., Kiemeney L.A., Schaafsma H.E., and Debruyne F.M. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urological Group. Br J Urol 73 (1994) 172
21. Witjes J.A., Moonen P.M., and van der Heijden A.G. Review pathology in a diagnostic bladder cancer trial: effect of patient risk category. Urology 67 (2006) 751